Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice. [electronic resource]
Producer: 20191029Description: 4648-4656 p. digitalISSN:- 2284-0729
- Animals
- Connective Tissue Growth Factor -- antagonists & inhibitors
- Cyclic AMP -- physiology
- Fibrosis
- Hypoglycemic Agents -- pharmacology
- Liraglutide -- pharmacology
- Male
- Mice
- Mice, Inbred C57BL
- Myocardial Infarction -- drug therapy
- Myocardium -- pathology
- Transforming Growth Factor beta1 -- genetics
- Ventricular Remodeling -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.